Insulin-like growth factor binding protein 2 (IGFBP-2) regulates blood glucose levels, facilitates hippocampal synaptic plasticity and may have a predictive value for Alzheimer’s disease (AD) diagnosis.
Methods:
IGFBP-2 levels were studied in plasma in 566 subjects and in cerebrospinal fluid (CSF) in 245 subjects across the AD spectrum from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Variants in the IGFBP-2 gene were examined. Linear mixed modeling in SPSS tested main effects of IGFBP-2 and interactions with APOE4 on neurocognitive indices and biomarkers. Voxel-wise regression was used to gauge IGFBP-2 and regional grey matter and glucose metabolism associations.
Results:
Each point increase in IGFBP-2 corresponded to a three times greater likelihood of having mild cognitive impairment (MCI) or AD. IGFBP-2 showed beneficial associations with respect to cognitive scores in individuals with two APOE4 alleles. Higher IGFBP-2 predicted higher insulin resistance, but not CSF amyloid or tau. Voxel-wise analyses showed that plasma IGFBP-2 predicted lower grey matter volume and FDG metabolism in a large area spanning the frontal, temporal, and occipital lobes. CSF IGFBP-2 levels showed similar voxel-wise analysis results, but were uniquely associated with CSF amyloid and tau. Analysis of single nucleotide polymorphisms (SNPs) in IGFBP-2 showed that subjects carrying risk alleles versus common alleles had increased risk of AD and lower memory scores. Voxel-wise analyses of these SNPs also implicated the hippocampus and prefrontal cortex.
Conclusions:
IGFBP-2 is associated with AD risk and outcomes; plasma IGFBP-2 provides stronger predictive power for brain outcomes, while CSF IGFBP-2 provides improved predictive accuracy for AD CSF biomarkers.
FernandezAM, Torres-AlemanI (2012) The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci13, 225–239.
2.
HoeflichA, RussoVC (2015) Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential. Best Pract Res Clin Endocrinol Metab29, 685–700.
3.
JonesJI, ClemmonsDR (1995) Insulin-like growth-factors and their binding-proteins - biological actions. Endocr Rev16, 3–34.
4.
CarrickFE, ForbesBE, WallaceJC (2001) BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains. J Biol Chem276, 27120–27128.
5.
ReyerA, SchindlerN, OhdeD, WalzC, KunzeM, TuchschererA, WirthgenE, BrenmoehlJ, HoeflichA (2015) The RGD sequence present in IGFBP-2 is required for reduced glucose clearance after oral glucose administration in female transgenic mice. Am J Physiol Endocrinol Metab309, E409–417.
CountsDR, GwirtsmanH, CarlssonLM, LesemM, CutlerGBJr (1992) The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab75, 762–767.
8.
NarayananRP, FuB, HealdAH, SiddalsKW, OliverRL, HudsonJE, PaytonA, AndersonSG, WhiteA, OllierWE, GibsonJM (2012) IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes. Endocr Connect1, 95–102.
9.
HuD, PawlikowskaL, KanayaA, HsuehWC, ColbertL, NewmanAB, SatterfieldS, RosenC, CummingsSR, HarrisTB, ZivE, Health, Aging, and Body Composition Study (2009) Serum insulin-like growthfactor-1 binding proteins 1 and 2 and mortality in older adults:The health, aging, and body composition study. J Am GeriatrSoc57, 1213–1218.
10.
WilletteAA, BendlinBB, StarksEJ, BirdsillAC, JohnsonSC, ChristianBT, OkonkwoOC, La RueA, HermannBP, KoscikRL, JonaitisEM, SagerMA, AsthanaS (2015) Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol72, 1013–1020.
11.
WilletteAA, XuG, JohnsonSC, BirdsillAC, JonaitisEM, SagerMA, HermannBP, La RueA, AsthanaS, BendlinBB (2013) Insulin resistance, brain atrophy, and cognitive performance in late middle–aged adults. Diabetes Care36, 443–449.
12.
BakerLD, CrossD, MinoshimaS, BelongiaD, WatsonGS, CraftS (2011) Insulin resistance is associated with Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with pre-diabetes or early type 2 diabetes. Arch Neurol68, 51–57.
13.
SchindlerN, MayerJ, SaengerS, GimsaU, WalzC, BrenmoehlJ, OhdeD, WirthgenE, TuchschererA, RussoVC, FrankM, KirschsteinT, MetzgerF, HoeflichA (2016) Phenotype analysis of male transgenic mice overexpressing mutant IGFBP-2 lacking the Cardin-Weintraub sequence motif: Reduced expression of synaptic markers and myelin basic protein in the brain and a lower degree of anxiety-like behaviour. Growth Horm IGF Res33, 1–8.
HertzeJ, NaggaK, MinthonL, HanssonO (2014) Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: An observational study. BMC Neurol14, 64.
16.
CraftS, AsthanaS, CookDG, BakerLD, CherrierM, PurgananK, WaitC, PetrovaA, LatendresseS, WatsonGS, NewcomerJW, SchellenbergGD, KrohnAJ (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology28, 809–822.
17.
ArafatAM, WeickertMO, FrystykJ, SprangerJ, SchoflC, MohligM, PfeifferAF (2009) The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab94, 5093–5101.
18.
SpellmanDS, WildsmithKR, HonigbergLA, TuefferdM, BakerD, RaghavanN, NairnAC, CroteauP, SchirmM, AllardR, LamontagneJ, ChelskyD, HoffmannS, PotterWZ, Alzheimer’s Disease Neuroimaging Initiative, Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team (2015) Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer’s Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin Appl9, 715–731.
19.
ShawLM, VandersticheleH, Knapik-CzajkaM, FigurskiM, CoartE, BlennowK, SoaresH, SimonAJ, LewczukP, DeanRA, SiemersE, PotterW, LeeVMY, TrojanowskiJQ, Alzheimer’s Disease Neuroimaging Initiative (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol121, 597–609.
20.
CranePK, CarleA, GibbonsLE, InselP, MackinRS, GrossA, JonesRN, MukherjeeS, CurtisSM, HarveyD, WeinerM, MungasD, Alzheimer’s Disease Neuroimaging Initiative (2012) Development andassessment of a composite score for memory in the Alzheimer’sDisease Neuroimaging Initiative (ADNI). Brain Imaging Behav6, 502–516.
21.
GibbonsLE, CarleAC, MackinRS, HarveyD, MukherjeeS, InselP, CurtisSM, MungasD, CranePK (2012) A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav6, 517–527.
DowlingNM, HermannB, La RueA, SagerMA (2010) Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer’s disease. Neuropsychology24, 742–756.
24.
WilletteAA, BendlinBB, StarksEJ, BirdsillAC, JohnsonSC, ChristianBT, OkonkwoOC, La RueA, HermannBP, KoscikRL, JonaitisEM, SagerMA, AsthanaS (2015) Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol72, 1013–1020.
25.
HollandBS, CopenhaverMD (1987) An improved sequentially rejective Bonferroni test procedure. Biometrics43, 417–423.
26.
WilkinsonL (1975) Response variable hypotheses in multivariate-analysis of variance. Psychol Bull82, 408–412.
27.
van LeeuwenEM, KanterakisA, DeelenP, KattenbergMV, Genome of the Netherlands C, SlagboomPE, de BakkerPI, WijmengaC, SwertzMA, BoomsmaDI, van DuijnCM, KarssenLC, HottengaJJ (2015) Population-specific genotype imputations using minimac or IMPUTE2. Nat Protoc10, 1285–1296.
28.
VannucciSJ, Koehler-StecEM, LiK, ReynoldsTH, ClarkR, SimpsonIA (1998) GLUT4 glucose transporter expression in rodent brain: Effect of diabetes. Brain Res797, 1–11.
29.
CraftS, BakerLD, MontineTJ, MinoshimaS, WatsonGS, ClaxtonA, ArbuckleM, CallaghanM, TsaiE, PlymateSR, GreenPS, LeverenzJ, CrossD, GertonB (2012) Intranasalinsulin therapy for Alzheimer disease and amnestic mild cognitiveimpairment: A pilot clinical trial. Arch Neurol69, 29–38.
30.
KeeneyJT, IbrahimiS, ZhaoL (2015) Human ApoE isoformsdifferentially modulate glucose and amyloid metabolic pathways infemale brain: Evidence of the mechanism of neurorotection byApoE2 and implications for Alzheimer’s disease prevention andearly intervention. J Alzheimers Dis48, 411–424.
